RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana

Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NasdaqGM: RPHM) (the “Company”) and OnKure, Inc. Upon completion of the proposed transaction, pre-merger Reneo shareholders are expected to own approximately 31% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Reneo shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-rphm/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514692097/en/

The Reneo Pharmaceuticals Stock at the time of publication of the news with a raise of +1,89 % to 1,620USD on Nasdaq stock exchange (15. Mai 2024, 02:00 Uhr).